Curaleaf (OTCMKTS:CURLF) Upgraded at Roth Capital

Curaleaf (OTCMKTS:CURLF) was upgraded by equities researchers at Roth Capital to a “strong-buy” rating in a note issued to investors on Sunday,Zacks.com reports. Roth Capital also issued estimates for Curaleaf’s Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.21) EPS.

A number of other analysts have also recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $6.25 price target on shares of Curaleaf in a research report on Thursday, August 8th. Cormark cut shares of Curaleaf from a “moderate buy” rating to a “hold” rating in a research note on Thursday, November 7th.

Curaleaf Stock Performance

Shares of Curaleaf stock opened at $2.04 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.51 and a debt-to-equity ratio of 0.85. Curaleaf has a 1-year low of $1.64 and a 1-year high of $6.40. The company’s fifty day simple moving average is $2.93 and its 200-day simple moving average is $3.75.

About Curaleaf

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.